Christopher Michael Bull
Geen lopende functies
Profiel
Christopher Michael Bull served as the Independent Non-Executive Chairman at African Dawn Capital Ltd.
from 2015 to 2015.
He also worked as a Director at Oxyrane UK Ltd.
Additionally, he pursued an undergraduate degree at the University of KwaZulu-Natal.
Eerdere bekende functies van Christopher Michael Bull
| Bedrijven | Functie | Einde |
|---|---|---|
| AFRICAN DAWN CAPITAL LIMITED | Voorzitter | 12-06-2015 |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Directeur/Bestuurslid | - |
Opleiding van Christopher Michael Bull
| University of KwaZulu-Natal | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AFRICAN DAWN CAPITAL LIMITED | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
